Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-Linked Severe Combined Immune Deficiency (XSCID) results in the Development of a Normal and Sustained Immune System: Interim Results of an ongoing Phase I/II Clinical Study

Journal: 
ASGCT
Publication Year: 
0
Authors: 
Ewelina Mamcarz
PubMed link: 
Public Summary: 
Scientific Abstract: